(Q33781675)

29 July 2017

1 reference

title

Strategies for better diabetes control in the US. (English)

1 reference

29 July 2017

Garber AJ

1

1 reference

29 July 2017

publication date

1 January 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

58 Suppl 1

1 reference

29 July 2017

page(s)

61-69

1 reference

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

29 July 2017

cites work

1 reference

12 December 2020

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

1 reference

12 December 2020

1 reference

12 December 2020

Troglitazone: a review of its use in the management of type 2 diabetes mellitus

1 reference

12 December 2020

1 reference

12 December 2020

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

1 reference

12 December 2020

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

12 December 2020

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

1 reference

12 December 2020

Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus

1 reference

12 December 2020

What is the benefit of increasing the sulfonylurea dose?

1 reference

12 December 2020

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

12 December 2020

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

1 reference

12 December 2020

10.2165/00003495-199958001-00014

Identifiers

DOI

0 references

Dimensions Publication ID

1006521314

0 references

1 reference